Tag Archives: NYSE:MRK

Merck & Company (MRK) Gets a Hold Rating from RBC Capital

RBC Capital analyst Randall Stanicky maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of $89.00. The company’s shares closed last Monday at $76.94. According to TipRanks.com, Stanicky is currently ranked

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Sol-Gel Technologies (NASDAQ: SLGL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Sol-Gel Technologies (SLGL – Research Report) with bullish sentiments. Merck & Company (MRK) Mizuho

Cantor Fitzgerald Remains a Buy on Merck & Company (MRK)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Merck & Company (MRK – Research Report) on January 5 and set a price target of $95.00. The company’s shares closed last Monday at $89.20. According to TipRanks.com, Chen is

Merck & Company (MRK) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $100.00. The company’s shares closed last Monday at $91.64, close to its 52-week high of $92.64.

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), PTC Therapeutics (NASDAQ: PTCT) and Ionis Pharmaceuticals (NASDAQ: IONS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK – Research Report), PTC Therapeutics (PTCT – Research Report) and Ionis Pharmaceuticals (IONS – Research Report). Merck & Company

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Aerie Pharma (NASDAQ: AERI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Aerie Pharma (AERI – Research Report) with bullish sentiments. Merck & Company (MRK) In